What diseases does Pirfenidone/Axri treat? Analysis of indications, clinical efficacy and applicable groups

Pirfenidone is a drug used to treat lung diseases, especially idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a progressive lung disease of unknown origin that typically manifests as pulmonary fibrosis, abnormal scarring of lung tissue, leading to a progressive loss of lung function. IPF patients usually experience symptoms such as shortness of breath, cough, and fatigue, and the disease progresses rapidly, and the patient's quality of life and survival are seriously affected.

Pirfenidone can slow down the progression of IPFthrough its unique anti-fibrotic effect. Its mechanism of action is mainly by inhibiting fibrosis-related molecular signaling pathways, such as inhibiting the overactivity of transforming growth factor β (TGF-β) and other cytokines, thereby slowing down the occurrence and progression of fibrosis. In addition, pirfenidone is also believed to have antioxidant and anti-inflammatory effects, which gives it unique advantages in the treatment of IPF.

Clinical studies have shown that pirfenidone can significantly improve the lung function of IPF patients, delay the decline of lung function, and reduce the risk of disease progression. One of the most famous studies is the CAPACITY study, which confirmed that pirfenidone can significantly reduce the decline of lung function in patients with IPF and improve the quality of life of patients.

In terms of indications, pirfenidone is mainly used to treat patients with idiopathic pulmonary fibrosis (IPF). It has been approved by many countries and regions for the treatment of this disease and is recommended as a standard treatment in multiple international guidelines. For screening of indications, patients usually need to be diagnosed to rule out other types of pulmonary fibrosis, and are not suitable for patients with severe liver or kidney disease.

In general, pirfenidone/Acere is currently one of the effective drugs for the treatment of idiopathic pulmonary fibrosis and has a significant effect on slowing down the course of the disease and improving patients' lung function and quality of life. Especially with early diagnosis and standardized treatment, pirfenidone can significantly improve the prognosis of patients.

Reference materials:https://www.esbriet.com/